Activation-induced necroptosis contributes to B-cell lymphopenia in active systemic lupus erythematosus

Cell Death and Disease

Volumn 5, Issue 9, 2014, Pages

  Fan, H ^a   Liu, F ^a   Dong, G ^a   Ren, D ^a   Xu, Y ^a   Dou, J ^a   Wang, T ^a   Sun, L ^b,c   Hou, Y ^a  

^a NANJING UNIVERSITY   (China)

^b THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

^c MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS INHIBITOR; B LYMPHOCYTE RECEPTOR; CD19 ANTIGEN; CD27 ANTIGEN; IMMUNOGLOBULIN M; NECROSTATIN 1; PROTEIN KINASE INHIBITOR; TOLL LIKE RECEPTOR 7; UNCLASSIFIED DRUG; ZVAD; TLR7 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL ACTIVATION; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPOXIA; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOPENIA; MICROARRAY ANALYSIS; MITOCHONDRIAL DNA DISORDER; MORTALITY; MOUSE; NECROPTOSIS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SYSTEMIC LUPUS ERYTHEMATOSUS; CYTOLOGY; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MALE; PATHOPHYSIOLOGY;

APOPTOSIS; B-LYMPHOCYTES; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; LYMPHOPENIA; MALE; TOLL-LIKE RECEPTOR 7;

EID: 84927713732     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.375     Document Type: Article

References (55)

1. Wahren-Herlenius M, Dorner T. Immunopathogenic mechanisms of systemic autoimmune disease. Lancet 2013; 382: 819-831.
2. Crispin JC, Liossis SN, Kis-Toth K, Lieberman LA, Kyttaris VC, Juang YT et al. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med 2010; 16: 47-57.
3. Odendahl M, Jacobi A, Hansen A, Feist E, Hiepe F, Burmester GR et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 2000; 165: 5970-5979.
4. Korganow AS, Knapp AM, Nehme-Schuster H, Soulas-Sprauel P, Poindron V, Pasquali JL et al. Peripheral B cell abnormalities in patients with systemic lupus erythematosus in quiescent phase: decreased memory B cells and membrane CD19 expression. J Autoimmun 2010; 34: 426-434.
5. Dolff S, Wilde B, Patschan S, Durig J, Specker C, Philipp T et al. Peripheral circulating activated B-cell populations are associated with nephritis and disease activity in patients with systemic lupus erythematosus. Scand J Immunol 2007; 66: 584-590.
6. Vital EM, Dass S, Buch MH, Henshaw K, Pease CT, Martin MF et al. B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum 2011; 63: 3038-3047.
7. Rodriguez-Bayona B, Ramos-Amaya A, Perez-Venegas JJ, Rodriguez C, Brieva JA. Decreased frequency and activated phenotype of blood CD27 IgD IgM B lymphocytes is a permanent abnormality in systemic lupus erythematosus patients. Arthritis Res Ther 2010; 12: R108.
8. Anolik JH, Looney RJ, Lund FE, Randall TD, Sanz I. Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets. Immunol Res 2009; 45: 144-158.
9. Sato S, Fujimoto M, Hasegawa M, Takehara K. Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum 2004; 50: 1918-1927.
10. Lipsky PE. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2001; 2: 764-766.
11. Liossis SN, Kovacs B, Dennis G, Kammer GM, Tsokos GC. B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events. J Clin Invest 1996; 98: 2549-2557.
12. Reininger L, Winkler TH, Kalberer CP, Jourdan M, Melchers F, Rolink AG. Intrinsic B cell defects in NZB and NZW mice contribute to systemic lupus erythematosus in (NZB x NZW)F1 mice. J Exp Med 1996; 184: 853-861.
13. Giltiay NV, Chappell CP, Sun X, Kolhatkar N, Teal TH,Wiedeman AE et al. Overexpression of TLR7 promotes cell-intrinsic expansion and autoantibody production by transitional T1 B cells. J Exp Med 2013; 210: 2773-2789.
14. Mina-Osorio P, LaStant J, Keirstead N, Whittard T, Ayala J, Stefanova S et al. Suppression of glomerulonephritis in lupus-prone NZB x NZW mice by RN486, a selective inhibitor of Bruton's tyrosine kinase. Arthritis Rheum 2013; 65: 2380-2391.
15. Cancro MP, D'Cruz DP, Khamashta MA. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest 2009; 119: 1066-1073.
16. Kil LP, Hendriks RW. Aberrant B cell selection and activation in systemic lupus erythematosus. Int Rev Immunol 2013; 32: 445-470.
17. Becker AM, Dao KH, Han BK, Kornu R, Lakhanpal S, Mobley AB et al. SLE peripheral blood B cell, T cell and myeloid cell transcriptomes display unique profiles and each subset contributes to the interferon signature. PLoS One 2013; 8: e67003.
18. Garaud JC, Schickel JN, Blaison G, Knapp AM, Dembele D, Ruer-Laventie J et al. B cell signature during inactive systemic lupus is heterogeneous: toward a biological dissection of lupus. PLoS One 2011; 6: e23900.
19. Graninger WB, Steiner CW, Graninger MT, Aringer M, Smolen JS. Cytokine regulation of apoptosis and Bcl-2 expression in lymphocytes of patients with systemic lupus erythematosus. Cell Death Differ 2000; 7: 966-972.
20. Ronnblom L, Eloranta ML. The interferon signature in autoimmune diseases. Curr Opin Rheumatol 2013; 25: 248-253.
21. Jacob N, Stohl W. Cytokine disturbances in systemic lupus erythematosus. Arthritis Res Ther 2011; 13: 228.
22. Puri KD, Di Paolo JA, Gold MR. B-cell receptor signaling inhibitors for treatment of autoimmune inflammatory diseases and B-cell malignancies. Int Rev Immunol 2013; 32: 397-427.
23. Santiago-Raber ML, Baudino L, Izui S. Emerging roles of TLR7 and TLR9 in murine SLE. J Autoimmun 2009; 33: 231-238.
24. Celhar T, Magalhaes R, Fairhurst AM. TLR7 and TLR9 in SLE: when sensing self goes wrong. Immunol Res 2012; 53: 58-77.
25. Poovassery JS, Bishop GA, Type I. IFN receptor and the B cell antigen receptor regulate TLR7 responses via distinct molecular mechanisms. J Immunol 2012; 189: 1757-1764.
26. Dhir V, Singh AP, Aggarwal A, Naik S, Misra R. Increased T-lymphocyte apoptosis in lupus correlates with disease activity and may be responsible for reduced T-cell frequency: a cross-sectional and longitudinal study. Lupus 2009; 18: 785-791.
27. Qing X, Putterman C. Gene expression profiling in the study of the pathogenesis of systemic lupus erythematosus. Autoimmun Rev 2004; 3: 505-509.
28. Golstein P, Kroemer G. Cell death by necrosis: towards a molecular definition. Trends Biochem Sci 2007; 32: 37-43.
29. Kim JS, He L, Lemasters JJ. Mitochondrial permeability transition: a common pathway to necrosis and apoptosis. Biochem Biophys Res Commun 2003; 304: 463-470.
30. Dashzeveg N, Taira N, Lu ZG, Kimura J, Yoshida K. Palmdelphin, a novel target of p53 with Ser46 phosphorylation, controls cell death in response to DNA damage. Cell Death Dis 2014; 5: e1221.
31. Tait SW, Oberst A, Quarato G, Milasta S, Haller M, Wang R et al. Widespread mitochondrial depletion via mitophagy does not compromise necroptosis. Cell Rep 2013; 5: 878-885.
32. Gianotti TF, Castano G, Gemma C, Burgueno AL, Rosselli MS, Pirola CJ et al. Mitochondrial DNA copy number is modulated by genetic variation in the signal transducer and activator of transcription 3 (STAT3). Metabolism 2011; 60: 1142-1149.
33. Murphy D, Parker J, Zhou M, Fadlelmola FM, Steidl C, Karsan A et al. Constitutively overexpressed 21 kDa protein in Hodgkin lymphoma and aggressive non-Hodgkin lymphomas identified as cytochrome B5b (CYB5B). Mol Cancer 2010; 9: 14.
34. Bonora M, Wieckowski MR, Chinopoulos C, Kepp O, Kroemer G, Galluzzi L et al. Molecular mechanisms of cell death: central implication of ATP synthase in mitochondrial permeability transition. Oncogene 2014; e-pub ahead of print 14 April 2014; doi:10.1038/ onc.2014.96.
35. Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A et al. Hypoxiainducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000; 60: 7075-7083.
36. Benita Y, Kikuchi H, Smith AD, Zhang MQ, Chung DC, Xavier RJ. An integrative genomics approach identifies hypoxia inducible factor-1 (HIF-1)-target genes that form the core response to hypoxia. Nucleic Acids Res 2009; 37: 4587-4602.
37. Maes H, Van Eygen S, Krysko DV, Vandenabeele P, Nys K, Rillaerts K et al. BNIP3 supports melanoma cell migration and vasculogenic mimicry by orchestrating the actin cytoskeleton. Cell Death Dis 2014; 5: e1127.
38. Kim SJ, Li J. Caspase blockade induces RIP3-mediated programmed necrosis in Toll-like receptor-activated microglia. Cell Death Dis 2013; 4: e716.
39. McQuade T, Cho Y, Chan FK. Positive and negative phosphorylation regulates RIP1-and RIP3-induced programmed necrosis. Biochem J 2013; 456: 409-415.
40. Ofengeim D, Yuan J. Regulation of RIP1 kinase signalling at the crossroads of inflammation and cell death. Nat Rev Mol Cell Biol 2013; 14: 727-736.
41. Jog NR, Dinnall JA, Gallucci S, Madaio MP, Caricchio R. Poly(ADP-ribose) polymerase-1 regulates the progression of autoimmune nephritis in males by inducing necrotic cell death and modulating inflammation. J Immunol 2009; 182: 7297-7306.
42. Jouan-Lanhouet S, Arshad MI, Piquet-Pellorce C, Martin-Chouly C, Le Moigne-Muller G, Van Herreweghe F et al. TRAIL induces necroptosis involving RIPK1/RIPK3-dependent PARP-1 activation. Cell Death Differ 2012; 19: 2003-2014.
43. Dorner T, Giesecke C, Lipsky PE. Mechanisms of B cell autoimmunity in SLE. Arthritis Res Ther 2011; 13: 243.
44. Jenks SA, Sanz I. Altered B cell receptor signaling in human systemic lupus erythematosus. Autoimmun Rev 2009; 8: 209-213.
45. Anolik JH. B cell biology: implications for treatment of systemic lupus erythematosus. Lupus 2013; 22: 342-349.
46. Doreau A, Belot A, Bastid J, Riche B, Trescol-Biemont MC, Ranchin B et al. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol 2009; 10: 778-785.
47. Sakata A, Kuwahara K, Ohmura T, Inui S, Sakaguchi N. Involvement of a rapamycinsensitive pathway in CD40-mediated activation of murine B cells in vitro. Immunol Lett 1999; 68: 301-309.
48. Chen C, Pore N, Behrooz A, Ismail-Beigi F, Maity A. Regulation of glut1 mRNA by hypoxiainducible factor-1. Interaction between H-ras and hypoxia. J Biol Chem2001; 276: 9519-9525.
49. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2: 38-47.
50. Hong SS, Lee H, Kim KW. HIF-1alpha: a valid therapeutic target for tumor therapy. Cancer Res Treat 2004; 36: 343-353.
51. Donjerkovic D, Scott DW. Activation-induced cell death in B lymphocytes. Cell Res 2000; 10: 179-192.
52. Rickard JA, O'Donnell JA, Evans JM, Lalaoui N, Poh AR, Rogers T et al. RIPK1 regulates RIPK3-MLKL-driven systemic inflammation and emergency hematopoiesis. Cell 2014; 157: 1175-1188.
53. Krysko DV, Vandenabeele P. From regulation of dying cell engulfment to development of anti-cancer therapy. Cell Death Differ 2008; 15: 29-38.
54. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genomewide expression patterns. Proc Natl Acad Sci USA 1998; 95: 14863-14868.
55. Chiang DY, Brown PO, Eisen MB. Visualizing associations between genome sequences and gene expression data using genome-mean expression profiles. Bioinformatics 2001; 17(Suppl 1): S49-S55.